| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3329919 | Critical Reviews in Oncology/Hematology | 2008 | 10 Pages |
Abstract
Multiple immune evasion strategies characterize the pathobiology of Hodgkin's lymphoma. These must be considered when developing and testing immunotherapeutic approaches for this disease. The clinical experience with adoptive immunotherapy of Epstein–Barr virus positive tumors, and with monoclonal antibodies directed against CD30, CD20, and other antigens, is herein reviewed.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Yvette L. Kasamon, Richard F. Ambinder,